EU GVP Pharmacovigilance Training for Marketing Authorisation Holders

Opens with a doctor telling a sales representative that a patient lost part of their sight, and a self-rating on your QPPV and master file. Covers two cases: EMA inspectors' 2024 report, where adverse reaction reporting, the quality management system and the master file were the most common areas of findings, and PRAC's June 2025 review of NAION with semaglutide, found across many sources. Turns them into four questions: do we capture every report, send it on time, look for patterns, and can we show it? Introduces JKL Pharma Europe and its three generics, clears four myths, and outlines the thirteen modules in three parts, the exercises, the final exam and the certificate. It ends with a recap and three practice questions.

What you will be able to do

• Explain why basic case handling is where inspectors find most gaps
• Apply four questions to your own safety system
• Describe how the course, exercises and final exam work

Why it matters

Seeing what inspectors find most often tells you which everyday safety tasks to check first in your own team.

Practice: Practice: Why pharmacovigilance matters · 3 questions

Starts with a Spanish agency request on liver reactions with metformin that either stays in JKL's Spanish office or reaches the QPPV in Dublin the same day. Covers the rulebook: the Directive, the Regulation, the implementing regulation as amended in 2025, and EMA's GVP modules. Explains who is who: the marketing authorisation holder, national authorities, EMA, the PRAC, the CMDh for nationally authorised medicines, and EudraVigilance at the centre. Shows JKL's role map, the first page of its safety manual, with written agreements and subcontracts, and the evidence that roles are real, including ringing the QPPV's published number out of hours. Ends with reviewing the map whenever a law, module or partner changes. It ends with a recap and three practice questions.

What you will be able to do

• Name the EU legal texts and guidance that govern pharmacovigilance
• Explain the roles of the holder, EMA, PRAC and national authorities
• Build a role map that routes every question to the QPPV

Why it matters

Knowing who answers to whom means an authority's request gets one complete, on-time reply instead of a partial local one.

Practice: Practice: The EU framework and who does what · 3 questions

Opens with JKL's safety database down for three working days: with no plan, four serious cases pass day fifteen; with a business continuity procedure, a controlled log and triage keep them on time. Explains the quality cycle of plan, adhere, control and assure, and improve. Covers enough trained people, the procedures Article 11 of the implementing regulation lists, records kept for the right period, including master file elements for at least five years, and a training matrix by role. Shows JKL's monthly indicators, management review, and how a slow rise in late cases can reveal a staffing problem. Ends with three checks that show a working quality system, not just a quality manual. It ends with a recap and three practice questions.

What you will be able to do

• Describe the parts of a pharmacovigilance quality system
• Check that procedures listed in Article 11 are in place and followed
• Use indicators and trends to spot problems before reports are late

Why it matters

A quality system that is measured and tested keeps cases on time even when the safety database fails.

Practice: Practice: The system and its quality system · 3 questions

Starts with Irish inspectors at JKL Pharma Europe in Dublin finding a master file that names an old literature vendor and a replaced database, set against a current file whose logbook shows each change, who approved it and why. Adds a Milan generics company that moved its master file. Covers the QPPV, who resides and operates in the EU, is qualified and has enough authority, and backup arrangements for permanent and continuous cover. Explains the master file content set by Article 2, its annex, the logbook and what it need not record, location in the EU, and updating EMA's database within thirty calendar days. Shows JKL's last four logbook entries. In the exercise you check five entries against Articles 2 to 7. It ends with a recap, three practice questions and a practice exercise.

What you will be able to do

• Explain what the law requires of the QPPV and the deputy
• Check a master file against the content Article 2 requires
• Keep the master file and logbook current when things change

Why it matters

A master file that describes the system you run today lets inspectors spend their time on the work, not on doubts.

Practice: Practice: The QPPV and the master file · 3 questions

Opens with a Sunday social media post in the Netherlands about a rash from JKL's amoxicillin, hidden by a marketing agency in one version and sent to safety within one working day in the other. Adds a Lisbon pharmacist whose email through a general contact form was found the same morning. Covers the duty to record all suspected reactions from the EU and beyond, refuse no report, and keep them at one point in the EU. Explains spontaneous and solicited reports, digital media, literature screening with EMA's service, and special situations. Shows JKL's intake map, listing every door and its route, the short form for sales and medical staff, agreements, monthly reconciliations, training, and mock reports to test each door. It ends with a recap and three practice questions.

What you will be able to do

• Identify every route by which reports can reach the company
• Set agreements so partners send on side effects in time
• Test intake routes with mock reports and reconciliations

Why it matters

Making every door lead to the safety team stops reports being lost in marketing, call centres or partner inboxes.

Practice: Practice: Collecting adverse reaction reports · 3 questions

Starts with a second-hand call in Rotterdam about a fit after ceftriaxone, which is not yet a valid case until the patient herself calls on Thursday with her details. Covers the four minimum criteria: an identifiable reporter, an identifiable patient, a suspected reaction and a suspect medicine. Explains seriousness, day zero counted in calendar days from when anyone working for you knew, serious cases from anywhere within fifteen days and non-serious EU cases within ninety. Covers follow-up that restarts the clock for significant news, avoiding duplicates, masking personal data, and the mandatory E2B(R3) format. Shows a week of JKL's clock log in November 2026. In the exercise you set the deadline for each of JKL's cases. It ends with a recap, three practice questions and a practice exercise.

What you will be able to do

• Check a case for the four minimum criteria
• Set day zero and the correct EudraVigilance deadline
• Decide when follow-up restarts the clock

Why it matters

Getting day zero and validity right means cases go out on time without submitting reports nobody can assess.

Practice: Practice: Valid ICSRs and EudraVigilance · 3 questions

Opens with five reports of the same eye disorder with ceftriaxone over six months, each processed well but seen as a pattern only when JKL's monthly review groups related MedDRA terms and checks EudraVigilance and the literature. Explains what a signal is, and the steps from detection and validation to analysis, assessment and action, with Member States in the lead for nationally authorised medicines. Covers emerging safety issues, reported to the authorities and EMA within three working days, and the August 2025 change to the procedure for EudraVigilance signals. Shows a line from JKL's signal log, linked to case numbers, queries and meeting minutes, and comparing it with PRAC's published signals each month. It ends with a recap and three practice questions.

What you will be able to do

• Explain the difference between a case and a signal
• Follow the steps of signal management from detection to action
• Recognise an emerging safety issue and its reporting time

Why it matters

A signal review that groups cases means your company finds a pattern before an authority finds it for you.

Practice: Practice: Signal management · 3 questions

Starts with JKL's Mumbai team writing an annual PSUR for amoxicillin since 2016 out of habit, sent by email outside the EU route, without checking the EU list of reference dates. Explains what a PSUR evaluates and its format under the ICH periodic benefit-risk evaluation report guideline and GVP Module VII, and one PSUR per active substance. Covers the EURD list setting frequency and data lock point, reports due within seventy or ninety calendar days, why generics do not submit routinely unless the list requires it, and applying single assessment outcomes. Shows JKL's calendar and signal review timing for metformin. In the exercise you read the EURD entries for JKL's three substances. It ends with a recap, three practice questions and a practice exercise.

What you will be able to do

• Explain what a periodic safety update report must evaluate
• Read the EURD list to set frequency and data lock points
• Decide whether a generic must submit and how outcomes apply

Why it matters

Reading the list instead of following habit avoids both needless reports and missed ones.

Practice: Practice: Periodic safety update reports · 3 questions

Opens with an updated, published list of safety concerns for one of JKL's substances that JKL either misses for years or tracks and submits through the right variation. Covers the risk management system required for every medicine authorised since July 2012, and the seven parts set by the implementing regulation in a fixed template. Explains the safety specification: important identified risks, important potential risks and missing information, and why generics follow the reference product unless justified. Shows JKL's register, reviewed monthly and signed by the QPPV, and a tracker of commitments with owners and due dates, so each concern matches what the PSUR evaluates and the signal log watches. It ends with a recap and three practice questions.

What you will be able to do

• Describe the seven parts of a risk management plan
• Identify the safety concerns in a safety specification
• Keep the plan in line with signals and periodic reports

Why it matters

A plan kept current with published outcomes means your company can explain its risk measures to any authority.

Practice: Practice: Risk management plans · 3 questions

Starts with a required safety letter to doctors that JKL's local office either rewrites with its own wording or sends as the agreed text, on the agreed date, with all holders. Covers routine risk minimisation for every medicine and additional measures only where needed, such as guides, a checklist, a patient card or a diary, with templates in GVP Annex II, never promotional and always evaluated for effect. Explains safety letters to healthcare professionals with content and plan agreed with the authority, JKL's distribution log, public announcements reaching the authorities before or with the public, how JKL answers a journalist, and additional monitoring with the black triangle. Ends with rehearsing the first hour of a safety announcement. It ends with a recap and three practice questions.

What you will be able to do

• Tell routine from additional risk minimisation measures
• Agree a safety letter's content and plan with the authority
• Plan who speaks first when a new risk becomes public

Why it matters

One agreed message at the agreed time protects patients and keeps your company clear of conflicting statements.

Practice: Practice: Risk minimisation and communication · 3 questions

Opens with a study imposed by the Spanish agency on how a dosing warning is followed, where JKL's research partner starts collecting pharmacy data before the protocol is endorsed. Covers what a non-interventional safety study is and rules for every study: no promotion, payment only for time and expenses, watching for new risks, and reporting within twelve months. Explains extra rules for imposed studies: an endorsed protocol before data collection, approval of substantial amendments, a final report with an abstract in the set formats, entry in EMA's electronic study register since February 2026, and keeping the analytical dataset for inspection. Shows JKL registering its first study and one tracker linked to the risk plan and PSURs. It ends with a recap and three practice questions.

What you will be able to do

• Tell an imposed safety study from a voluntary one
• Check that an imposed study has an endorsed protocol before it starts
• Link study results to the risk plan and periodic reports

Why it matters

Following the study rules from the start means the data you collect counts and the company stays within the law.

Practice: Practice: Post-authorisation safety studies · 3 questions

Starts with JKL's case processing done by its parent's team in Mumbai: never audited in one version, so inspectors find a two-year literature gap, and audited every two years in the other. Adds a contract provider in Amsterdam sharing one audit calendar with clients. Covers the audit duty and its 2025 changes, independent auditors such as JKL's group team in Singapore, risk-based planning that covers all activities and every subcontractor, group companies included. Explains routine and for-cause inspections under the new GVP revision, what inspectors look at, the 2024 findings, corrective actions that fix the cause, and penalties. In the exercise you plan a risk-based audit programme for JKL and its subcontractors. It ends with a recap, three practice questions and a practice exercise.

What you will be able to do

• Plan a risk-based audit programme that includes subcontractors
• Explain what pharmacovigilance inspectors look at
• Turn findings into corrective actions that fix the cause

Why it matters

When your own auditor finds a weakness first, it is fixed before an inspector writes it up.

Practice: Practice: Audits and inspections · 3 questions

Opens with a hospital pharmacist in Hamburg calling JKL's German line on Thursday the fourth of March 2027 about a fifty-eight-year-old woman with severe breathing difficulty after ceftriaxone. Follows the case through the four questions on the call centre script, validity that day, submission to EudraVigilance in E2B(R3) on day five, follow-up on a new clock, quality checks, the QPPV's signed decision in the signal log, and an inspector's questions a year later. Shows what JKL puts on the table: call log, current master file and logbook, signal log, PSUR calendar and risk plan register. Gives a ten-step road map, the key takeaways, what is changing in EU law, and the final exam with its 60% mark.

What you will be able to do

• Follow a serious case through every part of the system
• Apply the ten-step road map to your own system
• List the records an inspector asks for on a single case

Why it matters

Tracing one case end to end shows whether your system really works, and where it would break.

Practice: Practice: Putting it together · 3 questions